Cargando…
Risk of Anaplastic Large-Cell Lymphoma (ALCL) in Cases of Late Seroma Formation After Breast Implant Insertion
Purpose: The aim of this study was to determine the odds ratio of anaplastic large-cell lymphoma in late seroma formation. Methods: In a PubMed search, 415 articles were found using the terms “breast implant AND seroma” (n = 232), “breast implant AND effusion” (n = 42), and “anaplastic large cell ly...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Open Science Company, LLC
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941142/ https://www.ncbi.nlm.nih.gov/pubmed/33747338 |
_version_ | 1783662097566007296 |
---|---|
author | Hwang, Kun Kim, Hun Kim, Hyung Mook Kim, Joo Ho |
author_facet | Hwang, Kun Kim, Hun Kim, Hyung Mook Kim, Joo Ho |
author_sort | Hwang, Kun |
collection | PubMed |
description | Purpose: The aim of this study was to determine the odds ratio of anaplastic large-cell lymphoma in late seroma formation. Methods: In a PubMed search, 415 articles were found using the terms “breast implant AND seroma” (n = 232), “breast implant AND effusion” (n = 42), and “anaplastic large cell lymphoma AND breast (n = 141). Sixty-seven abstracts were read, and 27 full articles were reviewed. Results: Three articles reported the incidence of late seroma in breast implants, with a total of 75 seromas out of 48,211 implants (0.16%). One article reported 48 cases of non-Hodgkin lymphoma from 43,537 implants (0.11%). Another article reported that 11 patients had anaplastic large-cell lymphoma among 389 primary lymphoma of the breast (2.83%). Two articles reported 143 seromas out of 236 anaplastic large-cell lymphomas (60.59%). The risk of anaplastic large-cell lymphoma was significantly higher in the patients having late seroma than those without seroma (odds ratio = 998.93; 95% confidence interval, 768.90-1297.78; P < .001). The incidence of anaplastic large-cell lymphoma in seroma was calculated by dividing the number of anaplastic large cell lymphomas with seroma (n = 143) by total seroma (N = 11,843), which resulted in an incidence of 1.21%. The expected incidence of anaplastic large-cell lymphoma in seroma was 1.21%. Conclusion: If late seroma develops after breast implant insertion, ultrasonography-guided aspiration should be performed, with enzyme-linked-immunosorbent serologic assay for CD30. |
format | Online Article Text |
id | pubmed-7941142 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Open Science Company, LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-79411422021-03-18 Risk of Anaplastic Large-Cell Lymphoma (ALCL) in Cases of Late Seroma Formation After Breast Implant Insertion Hwang, Kun Kim, Hun Kim, Hyung Mook Kim, Joo Ho Eplasty Review Purpose: The aim of this study was to determine the odds ratio of anaplastic large-cell lymphoma in late seroma formation. Methods: In a PubMed search, 415 articles were found using the terms “breast implant AND seroma” (n = 232), “breast implant AND effusion” (n = 42), and “anaplastic large cell lymphoma AND breast (n = 141). Sixty-seven abstracts were read, and 27 full articles were reviewed. Results: Three articles reported the incidence of late seroma in breast implants, with a total of 75 seromas out of 48,211 implants (0.16%). One article reported 48 cases of non-Hodgkin lymphoma from 43,537 implants (0.11%). Another article reported that 11 patients had anaplastic large-cell lymphoma among 389 primary lymphoma of the breast (2.83%). Two articles reported 143 seromas out of 236 anaplastic large-cell lymphomas (60.59%). The risk of anaplastic large-cell lymphoma was significantly higher in the patients having late seroma than those without seroma (odds ratio = 998.93; 95% confidence interval, 768.90-1297.78; P < .001). The incidence of anaplastic large-cell lymphoma in seroma was calculated by dividing the number of anaplastic large cell lymphomas with seroma (n = 143) by total seroma (N = 11,843), which resulted in an incidence of 1.21%. The expected incidence of anaplastic large-cell lymphoma in seroma was 1.21%. Conclusion: If late seroma develops after breast implant insertion, ultrasonography-guided aspiration should be performed, with enzyme-linked-immunosorbent serologic assay for CD30. Open Science Company, LLC 2021-03-08 /pmc/articles/PMC7941142/ /pubmed/33747338 Text en Copyright © 2021 The Author(s) http://creativecommons.org/licenses/by/2.0/ This is an open-access article whereby the authors retain copyright of the work. The article is distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Hwang, Kun Kim, Hun Kim, Hyung Mook Kim, Joo Ho Risk of Anaplastic Large-Cell Lymphoma (ALCL) in Cases of Late Seroma Formation After Breast Implant Insertion |
title | Risk of Anaplastic Large-Cell Lymphoma (ALCL) in Cases of Late Seroma Formation After Breast Implant Insertion |
title_full | Risk of Anaplastic Large-Cell Lymphoma (ALCL) in Cases of Late Seroma Formation After Breast Implant Insertion |
title_fullStr | Risk of Anaplastic Large-Cell Lymphoma (ALCL) in Cases of Late Seroma Formation After Breast Implant Insertion |
title_full_unstemmed | Risk of Anaplastic Large-Cell Lymphoma (ALCL) in Cases of Late Seroma Formation After Breast Implant Insertion |
title_short | Risk of Anaplastic Large-Cell Lymphoma (ALCL) in Cases of Late Seroma Formation After Breast Implant Insertion |
title_sort | risk of anaplastic large-cell lymphoma (alcl) in cases of late seroma formation after breast implant insertion |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941142/ https://www.ncbi.nlm.nih.gov/pubmed/33747338 |
work_keys_str_mv | AT hwangkun riskofanaplasticlargecelllymphomaalclincasesoflateseromaformationafterbreastimplantinsertion AT kimhun riskofanaplasticlargecelllymphomaalclincasesoflateseromaformationafterbreastimplantinsertion AT kimhyungmook riskofanaplasticlargecelllymphomaalclincasesoflateseromaformationafterbreastimplantinsertion AT kimjooho riskofanaplasticlargecelllymphomaalclincasesoflateseromaformationafterbreastimplantinsertion |